Pacira BioSciences Inc (NAS:PCRX)
$ 16.81 -0.7 (-4%) Market Cap: 776.17 Mil Enterprise Value: 998.18 Mil PE Ratio: 0 PB Ratio: 1.03 GF Score: 72/100

Q3 2022 Pacira Biosciences Inc Earnings Call Transcript

Nov 03, 2022 / 12:30PM GMT
Release Date Price: $49.59 (-2.73%)
Susan Mesco
Pacira BioSciences, Inc. - Head of Investor Relations

Good morning, everyone. Welcome to today's conference call to discuss our Third Quarter 2022 Financial Results. Joining me on today's call are Dave Stack, Chairman and Chief Executive Officer; Roy Winston, Chief Medical Officer; and Charlie Reinhart, Chief Financial Officer. Additional members of our executive team will join for today's question-and-answer session.

Before we begin, let me remind you that this call will include forward-looking statements based on current expectations. Such statements represent our judgment as of today and may involve risks and uncertainties. For information concerning risk factors that could affect the company, please refer to our SEC filings, which are available from the SEC or our website.

With that, I will now turn the call over to Dave Stack.

David M. Stack
Pacira BioSciences, Inc. - Chairman & CEO

Thank you, Susan. Good morning, everyone, and thank you for joining us. We'll begin today's discussion with prepared remarks to cover

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot